GILEAD SCIENCES, INC. (GILD) vs ELI LILLY & Co (LLY)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | GILD | LLY |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $29.44B | $65.18B |
| Revenue growth (YoY) | ▲ 2.4% | ▲ 44.7% |
| Net income | $8.51B | $20.64B |
| Gross margin | 78.8% | 83.0% |
| Diluted EPS | $6.78 | $22.95 |
| Insider net (6 mo) | +385.1K sh • 18 sells • 0 buys | −31.3K sh • 5 sells • 0 buys |
| Institutional owners | 46 | 51 |
| Institutional value held | $98.74B | $533.23B |
| Next earnings (est.) | Around Oct 29, 2026 | Around Oct 29, 2026 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About GILEAD SCIENCES, INC. (GILD)
Gilead Sciences, Inc. is a biopharmaceutical company headquartered in Foster City, California, operating in more than 35 countries, dedicated to discovering, developing and delivering innovative medicines addressing unmet medical needs in virology, oncology… Read more →
About ELI LILLY & Co (LLY)
Eli Lilly and Company, incorporated in Indiana in 1901 and tracing its roots to a drug manufacturing business founded in 1876, operates as a single-segment human pharmaceutical company focused on discovering, developing, manufacturing, and marketing… Read more →
Source: SEC EDGAR.